M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

Phase 2

Active, not recruiting

Conditions: Delirium
Locally Advanced Malignant Neoplasm
Metastatic Malignant Neoplasm
Recurrent Malignant Neoplasm
Advanced Malignant Neoplasm

Interventions: Drug: Haloperidol
Drug: Chlorpromazine
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2017-01-16

Last Posted Date: 2025-03-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT03021486

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
Neutropenia
Acute Myeloid Leukemia

Interventions: Drug: Isavuconazole

First Posted Date: 2017-01-13

Last Posted Date: 2021-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 65

Registration Number: NCT03019939

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma
Recurrent Indolent Adult Non-Hodgkin Lymphoma
Refractory Indolent Adult Non-Hodgkin Lymphoma
Refractory Follicular Lymphoma
Recurrent Follicular Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Drug: Cytarabine
Drug: Etoposide
Biological: Filgrastim
Drug: Lenalidomide
Drug: Melphalan
Biological: Rituximab

First Posted Date: 2017-01-12

Last Posted Date: 2023-02-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT03019640

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

Phase 1

Completed

Conditions: Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm
Refractory Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Drug: Metformin
Other: Pharmacological Study
Drug: Sapanisertib

First Posted Date: 2017-01-11

Last Posted Date: 2023-10-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT03017833

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Phase 1

Completed

Conditions: Clear Cell Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v7
Metastatic Kidney Carcinoma
Stage III Renal Cell Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Sitravatinib

First Posted Date: 2017-01-10

Last Posted Date: 2024-11-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT03015740

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Hypnosedation in Relaxing Patients Undergoing Breast Cancer Surgery

Not Applicable

Active, not recruiting

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Prognostic Stage 0 Breast Cancer AJCC v8
Prognostic Stage I Breast Cancer AJCC v8

Interventions: Other: Questionnaire Administration
Behavioral: Hypnosedation
Behavioral: Verbal Support

First Posted Date: 2017-01-06

Last Posted Date: 2025-04-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT03012399

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer

Recruiting

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage IVB Hypopharyngeal Carcinoma AJCC v8
Stage I Nasopharyngeal Carcinoma AJCC v8
Stage II Hypopharyngeal Carcinoma AJCC v8
Stage II Laryngeal Cancer AJCC v8
Stage II Nasopharyngeal Carcinoma AJCC v8
Stage IV Laryngeal Cancer AJCC v8
Metastatic Head and Neck Carcinoma

Interventions: Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2017-01-04

Last Posted Date: 2025-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 471

Registration Number: NCT03010150

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase 2

Active, not recruiting

Conditions: Recurrent Endometrial Carcinoma
Stage IIIA Uterine Corpus Cancer AJCC v8
Stage IVB Uterine Corpus Cancer AJCC v8
Recurrent Endometrial Endometrioid Adenocarcinoma
Refractory Endometrial Carcinoma
Refractory Endometrial Endometrioid Adenocarcinoma
Stage IVA Uterine Corpus Cancer AJCC v8
Stage III Uterine Corpus Cancer AJCC v8
Stage IIIC Uterine Corpus Cancer AJCC v8
Stage IIIC1 Uterine Corpus Cancer AJCC v8

Interventions: Drug: Everolimus
Drug: Letrozole
Drug: Ribociclib

First Posted Date: 2017-01-02

Last Posted Date: 2025-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT03008408

Locations: 🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Phase 2

Recruiting

Conditions: Malignant Mesothelioma
CD30-Positive Neoplastic Cells Present

Interventions: Drug: Brentuximab Vedotin
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-12-30

Last Posted Date: 2025-05-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 55

Registration Number: NCT03007030

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle

Not Applicable

Completed

Conditions: Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma
Lung Cancer

Interventions: Device: 25-Gauge Needle
Device: 22-Gauge Needle
Procedure: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)

First Posted Date: 2016-12-29

Last Posted Date: 2022-06-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 61

Registration Number: NCT03004586

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy